Reality Check on Non-Small Cell Lung Cancer EGFR Mutated
Market access for Non-small cell lung cancer EGFR Mutated treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 60% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In December 2020, the FDA approved an additional indication for AstraZeneca’s Tagrisso (osimertinib) for the adjuvant treatment of adults with early-stage epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer whose tumors have exon 19 deletions or exon 21 L858R mutations as detected by an FDA-approved test after tumor resection with curative intent
- Key Findings: Many drugs to treat NSCLC are on the market today, and multiple ones are in Phase III trials. The discovery of genetic alterations that drive tumor growth has changed the clinical management of the disease and produced specific targeted therapies to treat the various genetic mutations
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.